ReviewInflammatory bowel diseases2020
Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing.
Review in Inflammatory bowel diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 76 citations in OpenAlex.
- Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.Journal of patient-reported outcomes · 2025Trial
- Article
- Article
- Interpreting Biomarker Discordance in Inflammatory Bowel Disease: Beyond Fecal Calprotectin and C-Reactive Protein.Biomedicines · 2026Review
- Redefining Neutrophil Function in Inflammatory Bowel Disease: From Tissue Injury to Immune Resolution.Molecular biology reports · 2026Review
- Formyl peptide receptor 2 is a potential biomarker and therapeutic target for inflammatory bowel disease.Acta pharmacologica Sinica · 2026Article
- Western Diet Inhibits FUT7-Mediated Treg Intestinal Homing to Disrupt the Homeostasis of Intestinal Epithelial Cells in Crohn's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeted oral delivery of microencapsulated TNF-α siRNA in an experimental model of colitis.Drug delivery and translational research · 2026Article
- Developmentally endothelial locus-1 facilitates intestinal inflammation resolution by suppressing the Cmpk2-cGAS-STING pathway and promoting reparatory macrophage transition.Journal of advanced research · 2026Article
- Targeting SLC7 A11 Ameliorates Ulcerative Colitis by Promoting Efferocytosis Through the ERK1/2 Pathway.Inflammation · 2025Article
- Oral FPR2/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease.Acta pharmacologica Sinica · 2025Article
- Excretory/secretory products from Hymenolepis nana adult worms alleviate ulcerative colitis in mice via tuft/IL-13 signaling pathway.Parasites & vectors · 2025Article
- TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis.The Journal of clinical investigation · 2025Article
- LiveFoods (Basel, Switzerland) · 2025Article
- Kuiyangling Enema Alleviates Ulcerative Colitis Mice by Reducing Levels of Intestinal NETs and Promoting HuR/VDR Signaling.Journal of inflammation research · 2025Article
- Autophagy in inflammatory bowel disease: immunization, etiology, and therapeutic potential.Frontiers in immunology · 2025Review
- The role of efferocytosis in inflammatory bowel disease.Frontiers in immunology · 2025Review
- Hymenolepis nana antigens alleviate ulcerative colitis by promoting intestinal stem cell proliferation and differentiation via AhR/IL-22 signaling pathway.PLoS neglected tropical diseases · 2024Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Increased bronchiectasis risk and related risk factors in inflammatory bowel disease: a 10-year Korean national cohort study.ERJ open research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Despite significant recent therapeutic advances, complete mucosal healing remains a difficult treatment target for many patients with inflammatory bowel diseases (IBD) to achieve. Our review focuses on the translational concept of promoting resolution of inflammation and repair as a necessary adjunctive step to reach this goal. We explore the roles of inflammatory cell apoptosis and efferocytosis to promote resolution, the new knowledge of gut monocyte-macrophage populations and their secreted prorepair mediators, and the processes of gut epithelial repair and regeneration to bridge this gap. We discuss the need and rationale for this vision and the tangible steps toward integrating proresolution therapies in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.